Skip to main
LGVN

Longeveron (LGVN) Stock Forecast & Price Target

Longeveron (LGVN) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Longeveron Inc. is positioned favorably due to its innovative approach in developing Lomecel-B, a stem cell formulation with demonstrated safety and potential in treating conditions like Hypoplastic Left Heart Syndrome, Alzheimer's disease, and Aging-related Frailty. The Phase 1b ELPIS I study indicated remarkable 5-year transplant-free survival rates of 100% in Stage II HLHS patients, significantly exceeding the historical standard of care at 80%, enhancing the prospects for FDA approval as the ongoing Phase 2b study progresses. Moreover, a revised discounted cash flow analysis suggests a substantial potential for growth, indicating a notable upside in the company's stock value based on the promising clinical data and innovative business model.

Bears say

Longeveron Inc.'s stock has depreciated approximately 56% year-to-date, largely attributed to the clinical development risks associated with its investigational product, Lomecel-B, particularly regarding unexpected safety signals in HLHS patients. Furthermore, there are concerns related to the efficacy outcomes from the ongoing ELPIS II study and potential delays in securing necessary funding for further clinical development. Additional risks include challenges in obtaining regulatory approval, slower-than-anticipated market penetration, as well as potential dilution risks that could undermine investor confidence and diminish share value.

Longeveron (LGVN) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Longeveron and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Longeveron (LGVN) Forecast

Analysts have given Longeveron (LGVN) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Longeveron (LGVN) has a Strong Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Longeveron (LGVN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.